Compare BYND & DCTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BYND | DCTH |
|---|---|---|
| Founded | 2009 | 1988 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Packaged Foods | Medical/Dental Instruments |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 346.2M | 323.1M |
| IPO Year | 2018 | 2015 |
| Metric | BYND | DCTH |
|---|---|---|
| Price | $0.79 | $9.08 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 7 | 4 |
| Target Price | $1.70 | ★ $22.00 |
| AVG Volume (30 Days) | ★ 30.2M | 510.6K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 53.80 | ★ 107.53 |
| EPS | N/A | ★ 0.07 |
| Revenue | ★ $326,452,000.00 | N/A |
| Revenue This Year | N/A | $29.20 |
| Revenue Next Year | N/A | $29.54 |
| P/E Ratio | ★ N/A | $130.29 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.50 | $8.12 |
| 52 Week High | $7.69 | $18.23 |
| Indicator | BYND | DCTH |
|---|---|---|
| Relative Strength Index (RSI) | 48.49 | 43.97 |
| Support Level | $0.67 | $8.90 |
| Resistance Level | $0.82 | $10.39 |
| Average True Range (ATR) | 0.08 | 0.40 |
| MACD | 0.01 | -0.03 |
| Stochastic Oscillator | 28.25 | 33.14 |
Beyond Meat Inc is a provider of plant-based meat company offering a portfolio of revolutionary plant-based meats. It builds meat directly from plants, an innovation that enables consumers to experience the taste, texture and other sensory attributes of popular animal-based meat products while enjoying the nutritional and environmental benefits of eating plant-based meat product It has products such as burgers, sausage, ground beef, jerky, meatballs and chicken. The company generates revenue from sales of its products to the customers across mainstream grocery, mass merchandiser, club store, convenience store and natural retailer channels and various food-away-from-home channels, including restaurants, foodservice outlets and schools, mainly in the United States.
Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.